Results 241 to 250 of about 27,407 (265)

Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes

Annals of Pharmacotherapy, 2013

exaly  

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Endocrine Journal, 2020
Takashi Nomiyama, Tomohiro Numata, Ryuji Inoue   +2 more
exaly  

SGLT2 Inhibitor–Induced Sympathoinhibition

JACC Basic To Translational Science, 2020
Vance Matthews, Lakshini Herat
exaly  

A case in which SGLT2 inhibitor is a contributing factor to takotsubo cardiomyopathy and heart failure

Journal of Cardiology Cases, 2020
Hiroshi Sugino
exaly  

SGLT2 inhibitors in clinical practice

The Lancet Diabetes & Endocrinology
Lars, Rydén, Anna, Norhammar
openaire   +2 more sources

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

International Journal of Molecular Sciences, 2017
Hideyuki Sakoda, Hiroki Kokubo, Tomoichiro Asano   +2 more
exaly  

Kidney stones and SGLT2 inhibitors

Clinical and Experimental Nephrology
Satoru Kuriyama, Kimiyoshi Ichida
openaire   +2 more sources

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Bioorganic and Medicinal Chemistry, 2012
Masayuki Yokota, Eiji Kurosaki, Mitsuaki Ohta   +2 more
exaly  

Method for determining sensitivity to SGLT2 inhibitor and sensitivity marker for SGLT2 inhibitor

2020
TAKAYAMA TADATERU, USUI MASAHIRO, KUDO KEIKO   +2 more
openaire   +2 more sources

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse

Frontiers in Cardiovascular Medicine, 2016
Michio Shimabukuro, Hotimah Masdan Salim, Sata Masataka   +2 more
exaly